MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 66 filers reported holding MERSANA THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,593,154 | +1611.4% | 19,364,688 | +6127.4% | 0.83% | +1560.0% |
| Q2 2022 | $1,437,000 | +10.3% | 310,960 | -4.8% | 0.05% | +22.0% |
| Q1 2022 | $1,303,000 | -76.9% | 326,578 | -76.5% | 0.04% | -92.8% |
| Q2 2019 | $5,639,000 | -53.4% | 1,392,231 | -39.5% | 0.57% | -48.9% |
| Q1 2019 | $12,098,000 | +144.1% | 2,300,000 | +364.1% | 1.12% | +150.0% |
| Q3 2018 | $4,956,000 | – | 495,618 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |